Back to Report Store Home

Global Dermatology Drugs Market to 2024 – IL Signaling Inhibitors to Overtake TNF-a Inhibitors as Leading Commercial Drug Class with Dupixent and Cosentyx among Key Performers

  • Published: Dec-2018
  • Report Code: GBIHC486MR
  • Report Format: pdf


Dermatological conditions, diseases of the skin, hair and nails, are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established products, which are largely genericized. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline. This report covers all dermatological disorders, but there is a particular focus on three key diseases, atopic dermatitis, acne vulgaris and psoriasis, as these conditions have the largest pipelines within the therapy area as well as large prevalent populations. The market size for dermatology therapeutics was valued at $35.9 billion in 2017 and it is expected to grow at a compound annual growth rate (CAGR) of 7.18% to $58.2 billion in 2024.


  • How is the dermatology landscape expected to change?

  • Which drugs will face patent expiry, biosimilar competition and decreasing revenue over the forecast period?

  • Overall, there are 936 products in the dermatology pipeline, how does the composition of the pipeline compare with that of the existing market?

  • Which molecular targets are most prominent within the pipeline and how do the key indications differ in terms of their pipeline composition?

  • The market size for dermatology therapeutics is expected to grow, from $35.9 billion in 2017 to $58.2 billion in 2024, at a CAGR of 7.18%. Which products will contribute to market growth most, and which will achieve blockbuster status?

  • What types of companies are involved in the dermatology therapy area?

  • Will the current market leaders retain their dominance over the forecast period?

  • How many strategic consolidations have been completed in the past decade and which types of assets attract the largest deal values?

Reasons To Buy

  • This report will allow you to:

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the three key indications.

  • Visualize the composition of the dermatology market, highlighting the key commercial assets and players.

  • Understand how the patent expiries of the key, blockbuster anti-TNF drugs will affect the dermatology drugs market.

  • Identify trends and developments in the dermatology pipeline, and consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.

  • Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various dermatological conditions.

  • Identify which drug classes will see particularly strong market growth over the forecast period.

  • See how or if the companies marketing anti-TNF drugs facing patent expiry will be able to offset biosimilar erosion.

  • Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments